AVITA Medical, Inc. (NASDAQ:RCEL – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for AVITA Medical in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.23) for the year. The consensus estimate for AVITA Medical’s current full-year earnings is ($0.95) per share.
AVITA Medical (NASDAQ:RCEL – Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The business had revenue of $18.51 million for the quarter, compared to analysts’ expectations of $33.15 million.
Read Our Latest Report on RCEL
AVITA Medical Stock Up 1.2%
RCEL opened at $6.06 on Wednesday. AVITA Medical has a fifty-two week low of $5.46 and a fifty-two week high of $14.16. The company has a debt-to-equity ratio of 9.39, a quick ratio of 2.47 and a current ratio of 2.83. The company has a fifty day moving average of $7.78 and a two-hundred day moving average of $9.42. The stock has a market capitalization of $160.20 million, a price-to-earnings ratio of -2.54 and a beta of 1.55.
Institutional Trading of AVITA Medical
A number of institutional investors and hedge funds have recently modified their holdings of RCEL. AQR Capital Management LLC purchased a new stake in shares of AVITA Medical during the first quarter worth about $799,000. Wellington Management Group LLP acquired a new position in AVITA Medical during the first quarter worth about $669,000. Nuveen LLC acquired a new position in AVITA Medical during the first quarter worth about $584,000. Evernest Financial Advisors LLC acquired a new position in AVITA Medical during the first quarter worth about $411,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in AVITA Medical during the first quarter worth about $374,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.
AVITA Medical Company Profile
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Featured Stories
- Five stocks we like better than AVITA Medical
- How to start investing in penny stocks
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- Canadian Penny Stocks: Can They Make You Rich?
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.